Zugo-cel is an allogeneic CAR-T cell therapy targeting CD19+ B cells. Unlike autologous therapies, it is manufactured as an off-the-shelf product, potentially enabling rapid deployment for autoimmune diseases.
Phase 1 ongoing; SLE patient in remission at month 9; IND cleared for neurologic indications
Checked 10 Oct0 updates this week
Zugo-cel is made from donor cells with engineered safety switches to prevent graft-versus-host disease, allowing use without patient-specific manufacturing.
The therapy redirects T cells to seek and eliminate B cells that drive autoimmune diseases in lupus, scleroderma and other conditions.
Early data suggests sustained B cell depletion and clinical remission months after a single infusion.
| Spec | Zugo-cel (CTX112) |
|---|---|
| CAR-T type | Allogeneic (off-the-shelf)R (reported) |
| Target | CD19+ B cellsR (reported) |
| Indications | Autoimmune and neurologic diseasesR (reported) |
| SLE patient response | Drug-free DORIS remission at month 9 in first patientR (reported) |
| Enrollment (rheumatology basket) | 14+ patients; 10+ trial sitesR (reported) |
R reported by the company
CRISPR Therapeutics
CRISPR, Casgevy, in vivo liver editing
Swiss-American gene-editing company co-founded by Nobel winner Emmanuelle Charpentier. With Vertex it made Casgevy, the first approved CRISPR medicine, for sickle cell disease and beta thalassemia. Now it edits liver genes to treat heart disease.
